AP2241A - Pyrimidine derivatives for the treatment of abnormal cell growth. - Google Patents

Pyrimidine derivatives for the treatment of abnormal cell growth.

Info

Publication number
AP2241A
AP2241A AP2006003790A AP2006003790A AP2241A AP 2241 A AP2241 A AP 2241A AP 2006003790 A AP2006003790 A AP 2006003790A AP 2006003790 A AP2006003790 A AP 2006003790A AP 2241 A AP2241 A AP 2241A
Authority
AP
ARIPO
Prior art keywords
treatment
cell growth
abnormal cell
pyrimidine derivatives
pyrimidine
Prior art date
Application number
AP2006003790A
Other versions
AP2006003790A0 (en
Inventor
John Charles Kath
Michael Joseph Luzzio
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34966230&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2241(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AP2006003790A0 publication Critical patent/AP2006003790A0/en
Application granted granted Critical
Publication of AP2241A publication Critical patent/AP2241A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AP2006003790A 2004-05-14 2005-05-02 Pyrimidine derivatives for the treatment of abnormal cell growth. AP2241A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57131204P 2004-05-14 2004-05-14
PCT/IB2005/001201 WO2005111023A1 (en) 2004-05-14 2005-05-02 Pyrimidine derivatives for the treatment of abnormal cell growth

Publications (2)

Publication Number Publication Date
AP2006003790A0 AP2006003790A0 (en) 2006-10-31
AP2241A true AP2241A (en) 2011-06-01

Family

ID=34966230

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2006003790A AP2241A (en) 2004-05-14 2005-05-02 Pyrimidine derivatives for the treatment of abnormal cell growth.

Country Status (27)

Country Link
EP (1) EP1751143A1 (en)
JP (1) JP4099212B2 (en)
KR (1) KR100886990B1 (en)
CN (2) CN102127058A (en)
AP (1) AP2241A (en)
AR (1) AR049097A1 (en)
AU (2) AU2005243397A1 (en)
BR (1) BRPI0511138A (en)
CA (1) CA2566707A1 (en)
CR (1) CR8749A (en)
EA (1) EA200601796A1 (en)
EC (1) ECSP066997A (en)
GE (1) GEP20104875B (en)
GT (1) GT200500113A (en)
IL (1) IL178828A0 (en)
MA (1) MA28583B1 (en)
MX (1) MXPA06011890A (en)
NL (2) NL1029045C2 (en)
NO (1) NO20064576L (en)
NZ (1) NZ550448A (en)
PA (1) PA8632601A1 (en)
PE (1) PE20060240A1 (en)
TN (1) TNSN06370A1 (en)
TW (1) TWI303635B (en)
UY (1) UY28894A1 (en)
WO (1) WO2005111023A1 (en)
ZA (1) ZA200608394B (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4812763B2 (en) * 2004-05-18 2011-11-09 ライジェル ファーマシューティカルズ， インコーポレイテッド Cycloalkyl-substituted pyrimidinediamine compounds and uses thereof
US20070032514A1 (en) * 2005-07-01 2007-02-08 Zahn Stephan K 2,4-diamino-pyrimidines as aurora inhibitors
WO2007072158A2 (en) * 2005-12-21 2007-06-28 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
DK2146779T3 (en) * 2007-04-18 2016-11-28 Pfizer Prod Inc Sulfonylamid derivatives to treat abnormal cell growth.
AU2008275918B2 (en) * 2007-07-17 2014-01-30 Rigel Pharmaceuticals, Inc. Cyclic amine substituted pyrimidinediamines as PKC inhibitors
WO2009071535A1 (en) * 2007-12-03 2009-06-11 Boehringer Ingelheim International Gmbh Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation
MX2010012703A (en) * 2008-05-21 2010-12-21 Ariad Pharma Inc Phosphorous derivatives as kinase inhibitors.
US8410126B2 (en) * 2009-05-29 2013-04-02 Boehringer Ingelheim International Gmbh Pyrimidine inhibitors of PKTK2
EP2464633A1 (en) 2009-08-14 2012-06-20 Boehringer Ingelheim International GmbH Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
WO2014174745A1 (en) * 2013-04-26 2014-10-30 国立大学法人京都大学 Eg5 INHIBITOR
CN109608444B (en) * 2018-11-27 2022-02-11 中国药科大学 ERK inhibitor containing isoindolinone and preparation method and use thereof
CN111732548B (en) * 2020-06-11 2022-06-17 浙江大学 N2-carbamyl aromatic ring-2-aminopyrimidine derivatives and medical application thereof
WO2024140671A1 (en) * 2022-12-29 2024-07-04 南京昕瑞再生医药科技有限公司 Fused tricyclic derivative, pharmaceutical composition comprising same, and use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003030909A1 (en) * 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
WO2004056807A1 (en) * 2002-12-20 2004-07-08 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9721437D0 (en) * 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine
AR042586A1 (en) 2001-02-15 2005-06-29 Sugen Inc 3- (4-AMIDOPIRROL-2-ILMETILIDEN) -2-INDOLINONE AS INHIBITORS OF PROTEIN KINASE; YOUR PHARMACEUTICAL COMPOSITIONS; A METHOD FOR THE MODULATION OF THE CATALYTIC ACTIVITY OF PROTEINQUINASE; A METHOD TO TREAT OR PREVENT AN AFFECTION RELATED TO PROTEINQUINASE
UA80767C2 (en) * 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003030909A1 (en) * 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
WO2004056807A1 (en) * 2002-12-20 2004-07-08 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
C. T. SUPURAN; A. SCOZZAFAVA: "Protein kinase inhibitors as anticancer agents" EXPERT OPIN. THER. PATENTS, vol. 14, no. 1, January 2004 (2004-01), pages 35-53 *

Also Published As

Publication number Publication date
NL1031845C2 (en) 2006-11-23
GT200500113A (en) 2006-01-10
AP2006003790A0 (en) 2006-10-31
PA8632601A1 (en) 2006-06-02
JP4099212B2 (en) 2008-06-11
GEP20104875B (en) 2010-01-11
WO2005111023A1 (en) 2005-11-24
EP1751143A1 (en) 2007-02-14
NL1031845A1 (en) 2006-07-31
MA28583B1 (en) 2007-05-02
CN102127058A (en) 2011-07-20
BRPI0511138A (en) 2007-11-27
NZ550448A (en) 2010-11-26
JP2007537234A (en) 2007-12-20
CR8749A (en) 2006-12-05
UY28894A1 (en) 2005-12-30
KR100886990B1 (en) 2009-03-04
CA2566707A1 (en) 2005-11-24
IL178828A0 (en) 2007-03-08
AR049097A1 (en) 2006-06-28
AU2005243397A1 (en) 2005-11-24
AU2009238255A1 (en) 2009-12-03
KR20070012477A (en) 2007-01-25
TW200539871A (en) 2005-12-16
CN1953974A (en) 2007-04-25
ECSP066997A (en) 2007-02-28
TWI303635B (en) 2008-12-01
NO20064576L (en) 2006-11-07
NL1029045A1 (en) 2005-11-15
PE20060240A1 (en) 2006-04-01
NL1029045C2 (en) 2006-06-02
MXPA06011890A (en) 2006-12-14
ZA200608394B (en) 2008-05-28
EA200601796A1 (en) 2007-04-27
TNSN06370A1 (en) 2008-02-22

Similar Documents

Publication Publication Date Title
ZA200804488B (en) Pyrimidine derivatives for the treatment of abnormal cell growth
AP2385A (en) Pyrimidine derivatives for the treatment of abnormal cell growth.
AU2003288603A8 (en) Pyrimidine derivates for the treatment of abnormal cell growth
TWI369205B (en) Sulfonyl amide derivatives for the treatment of abnormal cell growth
IL183706A0 (en) 2,4(4,6) pyrimidine derivatives
EG25081A (en) Use of prolines for improving growth and/or yield.
IL185912A0 (en) Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives
AP2378A (en) Sulfonamide derivatives for the treatment of diseases.
AP2359A (en) Sulfonamide derivatives for the treatment of diseases.
WO2006124713A3 (en) 4-biarylyl-1-phenylazetidin-2-ones
AP2241A (en) Pyrimidine derivatives for the treatment of abnormal cell growth.
PL1784399T3 (en) Pyrimidine derivatives
IL177232A0 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
IL179914A0 (en) Pyrimidine derivatives
PL1924717T3 (en) Methods for enhancing the dewaterability of sludge with alpha-amylase treatment
PL377686A1 (en) 4-anilino quinazoline derivatives for the treatment of abnormal cell growth
EG25401A (en) Process for the preparation of urea.
EP1750698A4 (en) 5-anilino-4-heteroarylpyrazole derivatives useful for the treatment of diabetes
GB0421359D0 (en) Method for the inactivation of enzymes
ZA200608015B (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
PL372031A1 (en) Preparation for the sanitizing and stabilizing sludge as well as method for the sanitizing and stabilizing sludge
HK1100928A (en) Imidazolo-5-yl-2-anilinopyrimidines as agents for the inhibition of cell proliferation
HK1118290A (en) Heteroarylcarbamoylbenzene derivatives for the treatment of diabetes
HK1114093A (en) Imidazolo-5-yl-2-anilo-pyrimidines as agents for the inhibition of cell proliferation
PL375287A1 (en) New derivative of isoxazol [4,5-d] pyrimidine and method for the manufacture of the new derivative of isoxazol [4,5-d] pyrimidine